<DOC>
	<DOCNO>NCT02377362</DOCNO>
	<brief_summary>This 3-part study explore safety tolerability GLWL-01 overweight/obese healthy participant single dos ( Part A ) , participant type 2 diabetes mellitus multiple dos 28-day period ( Parts B C ) .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability , Pharmacokinetics , Pharmacodynamics GLWL-01</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>PARTS AC : Nonvasectomized male ( vasectomize less 4 month prior study start ) must agree use condom spermicide abstain sexual intercourse study 90 day beyond last dose study drug Males agree donate sperm dose 90 day dose Laboratory test result within normal range acceptable deviation , Aspartate Aminotransferase ( AST ) / Alanine Aminotransferase ( ALT ) / Gamma Glutamyl Transferase ( GGT ) / Alkaline Phosphatase ( ALP ) less equal ( ≤ ) 1.5 x upper limit normal ( ULN ) , total bilirubin within normal limit Estimated glomerular filtration rate ( eGFR ) great equal ( ≥ ) 60 milliliter ( mL ) /minute/1.73m2 No evidence weight excursion beyond 5 % baseline weight within 3 month screen PART A Only : Overtly healthy male female , determine medical history physical examination Males must 18 65 year old ; female must 40 65 year old Female participant must : 1 . Women prior history hysterectomy least 45 year age folliclestimulating hormone ( FSH ) great ( &gt; ) 40 milliinternational unit per milliliter ( mIU/mL ) , 2 . Menopausal woman either : spontaneous amenorrhea least 12 month ( induced medical condition medication ) ; spontaneous amenorrhea 6 12 month FSH &gt; 40 mIU/mL Body mass index ( BMI ) 28 35 kilogram divide height meter square ( kg/m2 ) Normotensive ( supine systolic blood pressure ( BP ) less ( &lt; ) 140 millimeter mercury ( mmHg ) diastolic BP &lt; 90 mmHg No evidence weight excursion beyond 5 % baseline weight within 3 month screen PARTS B C : Must Type 2 Diabetes Mellitus Be 18 70 year old Have BMI 28 42 kg/m2 Female participant must nonchildbearing potential , must undergo one follow sterilization procedure least 6 month prior first dose : hysteroscopic sterilization , bilateral tubal ligation bilateral salpingectomy , hysterectomy , bilateral oophorectomy ; postmenopausal amenorrhea least 1 year prior first dose FSH serum level consistent postmenopausal status Normotensive ( supine systolic BP ) &lt; 150 mmHg diastolic BP &lt; 95 mmHg wellcontrolled hypertension stable hypertensive PARTS AC : Currently enrol clinical trial medical research judge compatible study , participate last 30 day prior dose clinical trial involve investigational product nonapproved use drug short halflife , within 5 halflives investigational product halflife longer 6 day Abnormality 12lead electrocardiogram ( ECG ) include correct QT ( QTc ) interval Bazett 's correction &gt; 450 millisecond ( msec ) men &gt; 470 msec woman , abnormality , opinion Investigator , increase risk associate participate study Significant cardiovascular disease disorder Evidence human immunodeficiency virus ( HIV ) infection , hepatitis B , hepatitis C , chronic liver biliary disease Average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) , unwilling stop use Cytochrome P450 ( CYP3A ) inhibitors/inducers ( St. John 's Wort ) alcohol consumption study , regular use know drug abuse positive find urinary drug screen , use cigarette nicotine product within last 3 month , blood donation loss within 56 day prior study Neuropsychiatric disease pharmacological therapy condition within 1 year dosing , antidepressant antipsychotic within 3 month dose , surgery within last 60 day Eating disorder weight loss medication within 4 month dose , bariatric surgery Unsuitable inclusion study opinion investigator sponsor PART A Only : History hypertension ( treatment antihypertensive ) Endocrine illness diabetes , growth hormone insufficiency / acromegaly , adrenal gland thyroid illness PARTS B C : Currently take simvastatin &gt; 10 mg per day , atorvastatin &gt; 20 mg per day , lovastatin &gt; 20 mg per day , history statininduced myopathy / rhabdomyolysis . Participants take dose simvastatin exclude cohort Allergic component Mixed Meal Tolerance Test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>